Hans Hammers, MD, PhD

Articles

Dr. Hammers on the Importance of Assessing Quality of Life in RCC

May 12th 2021

Hans Hammers, MD, PhD, discusses the importance of assessing quality of life in renal cell carcinoma.

Dr. Hammers on the Efficacy of Lenvatinib/Pembrolizumab in Advanced RCC

April 5th 2021

Hans Hammers, MD, PhD, discusses the efficacy of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.

Dr. Hammers on Investigational Strategies to Inflame Tumors in RCC

October 28th 2020

Hans Hammers, MD, PhD, discusses investigational strategies that are being used to inflame tumors in renal cell carcinoma.

Dr. Hammers on Challenges With CAR T-Cell Therapy in RCC

September 16th 2019

Hans Hammers, MD, PhD, associate professor of internal medicine, Division of Hematology-Oncology, UT Southwestern Medical Center, discusses the challenges with using CAR T-cell therapy in renal cell carcinoma.

Dr. Hammers on the Future of Immunotherapy in RCC

February 7th 2018

Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the future of immunotherapy for patients with renal cell carcinoma (RCC).

Dr. Hammers on the Long-Term Benefits of the CheckMate-214 Study in RCC

January 11th 2018

Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the long-term benefits of the CheckMate-214 study in patients with renal cell carcinoma (RCC).

Dr. Hammers on the CheckMate-214 Study for RCC

December 6th 2017

Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the CheckMate-214 study for patients with renal cell carcinoma (RCC).

Dr. Hammers Discusses Combining IDO and PD-1 Inhibitors in RCC

December 1st 2017

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the potential combination of IDO inhibitors and PD-1 inhibitors in renal cell carcinoma.

Dr. Hammers on Combination of Vaccines and Immune Checkpoint Inhibitors in RCC

May 5th 2017

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the combination of vaccines and immune checkpoint inhibitors in the treatment of patients with renal cell carcinoma.

Dr. Hammers Discusses Immunotherapy in RCC

March 2nd 2017

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses immunotherapy in renal cell carcinoma (RCC).